LONDON, Nov. 20, 2017 /PRNewswire/ -- This report on the global cardiovascular drugs market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments.
Download the full report: https://www.reportbuyer.com/product/5207218
The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2017 to 2025, considering the macro and micro environmental factors. Growth rates for each segment within the global cardiovascular drugs market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.
A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global cardiovascular drugs market across regions.Market revenue in terms of US$ Mn for the period between 2015 and 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025 are provided for all the segments, considering 2016 as the base year and 2015 as historic year. Market size estimations involved in-depth study of product features of different drug class and various pipeline products. Additionally, market related factors such as preference for self-medication, regional availability of specialty drugs, patent expiration of cardiovascular drugs & availability of generic drugs, projected launch of new drugs etc. in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.Cardiovascular Drugs Market: SegmentationCardiovascular diseases are estimated to affect population across the globe. Cardiovascular diseases comprise diseases and disorders related to heart and blood vessels. Various drugs are available and are under development for treating cardiovascular diseases based on various indications, such as arrhythmia, myocardial infarction, atherosclerosis, etc.Based on drug class, the global cardiovascular drugs market has been segmented into anti hyperlipidemics, anti-hypertensives, anti-coagulants, anti-fibrinolytics, anti-arrhythmic, and others. The others segment of drug class include drugs such as cardiac glycosides, antianginal drugs, and ant ischemic drugs. Anti-hypertensive drugs segment is projected to hold dominant share of global cardiovascular drugs market while anti-hyperlipidemics segment is likely to register steady growth during the forecast period from 2017 to 2025.Based on the distribution channel, the global cardiovascular drugs market is segmented into retail pharmacies, hospital pharmacies and online pharmacies. High incidences of hospital visits for cardiovascular disease consultation and rise in emergency department visits is likely to contribute for steady growth of hospital pharmacies segment.Cardiovascular Drugs Market: Geographical and Competitive DynamicsGeographically, the global cardiovascular drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented by major countries from each region.The report also profiles major players in the cardiovascular drugs market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include AstraZeneca plc., Pfizer Inc., Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Bayer AG, Sanofi, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Gilead Sciences, Inc., Johnson & Johnson, Astellas Pharma, Inc., Eli Lilly and Company, Otsuka Holdings Co., Ltd., Takeda Pharmaceutical Company Limited.
The global cardiovascular drugs market has been segmented as below:Global Cardiovascular Drugs Market, by Drug ClassAnti hyperlipidemicsAntihypertensiveAnti-coagulantsAntifibrinolyticAntiarrhythmicOthers ( Cardiac Glycosides, antianginal drugs, anti-ischemic drugs)Global Cardiovascular Drugs Market, by Distribution ChannelRetail PharmaciesHospital PharmaciesOnline PharmaciesGlobal Cardiovascular Drugs Market, by GeographyNorth AmericaU.S.CanadaEuropeGermanyFranceU.K.SpainItalyRest of EuropeAsia PacificIndiaChinaJapanAustralia & New ZealandRest of Asia PacificLatin AmericaBrazilMexicoRest of Latin AmericaMiddle East & AfricaGCC CountriesSouth AfricaRest of Middle East and AfricaDownload the full report: https://www.reportbuyer.com/product/5207218 About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com
Advertisement
Download the full report: https://www.reportbuyer.com/product/5207218
The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2017 to 2025, considering the macro and micro environmental factors. Growth rates for each segment within the global cardiovascular drugs market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.
Advertisement
A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global cardiovascular drugs market across regions.Market revenue in terms of US$ Mn for the period between 2015 and 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025 are provided for all the segments, considering 2016 as the base year and 2015 as historic year. Market size estimations involved in-depth study of product features of different drug class and various pipeline products. Additionally, market related factors such as preference for self-medication, regional availability of specialty drugs, patent expiration of cardiovascular drugs & availability of generic drugs, projected launch of new drugs etc. in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.Cardiovascular Drugs Market: SegmentationCardiovascular diseases are estimated to affect population across the globe. Cardiovascular diseases comprise diseases and disorders related to heart and blood vessels. Various drugs are available and are under development for treating cardiovascular diseases based on various indications, such as arrhythmia, myocardial infarction, atherosclerosis, etc.Based on drug class, the global cardiovascular drugs market has been segmented into anti hyperlipidemics, anti-hypertensives, anti-coagulants, anti-fibrinolytics, anti-arrhythmic, and others. The others segment of drug class include drugs such as cardiac glycosides, antianginal drugs, and ant ischemic drugs. Anti-hypertensive drugs segment is projected to hold dominant share of global cardiovascular drugs market while anti-hyperlipidemics segment is likely to register steady growth during the forecast period from 2017 to 2025.Based on the distribution channel, the global cardiovascular drugs market is segmented into retail pharmacies, hospital pharmacies and online pharmacies. High incidences of hospital visits for cardiovascular disease consultation and rise in emergency department visits is likely to contribute for steady growth of hospital pharmacies segment.Cardiovascular Drugs Market: Geographical and Competitive DynamicsGeographically, the global cardiovascular drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented by major countries from each region.The report also profiles major players in the cardiovascular drugs market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include AstraZeneca plc., Pfizer Inc., Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Bayer AG, Sanofi, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Gilead Sciences, Inc., Johnson & Johnson, Astellas Pharma, Inc., Eli Lilly and Company, Otsuka Holdings Co., Ltd., Takeda Pharmaceutical Company Limited.
The global cardiovascular drugs market has been segmented as below:Global Cardiovascular Drugs Market, by Drug ClassAnti hyperlipidemicsAntihypertensiveAnti-coagulantsAntifibrinolyticAntiarrhythmicOthers ( Cardiac Glycosides, antianginal drugs, anti-ischemic drugs)Global Cardiovascular Drugs Market, by Distribution ChannelRetail PharmaciesHospital PharmaciesOnline PharmaciesGlobal Cardiovascular Drugs Market, by GeographyNorth AmericaU.S.CanadaEuropeGermanyFranceU.K.SpainItalyRest of EuropeAsia PacificIndiaChinaJapanAustralia & New ZealandRest of Asia PacificLatin AmericaBrazilMexicoRest of Latin AmericaMiddle East & AfricaGCC CountriesSouth AfricaRest of Middle East and AfricaDownload the full report: https://www.reportbuyer.com/product/5207218 About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com
View original content:http://www.prnewswire.com/news-releases/cardiovascular-drugs-market---global-industry-analysis-size-share-growth-trends-and-forecast-2017---2025-300559879.html
SOURCE ReportBuyer
